Literature DB >> 8449836

Determinants of the activity of beta-lactamase inhibitor combinations.

D M Livermore1.   

Abstract

Inhibitor combinations provide one strategy to overcome beta-lactamase-mediated resistance. Their success depends, obviously, on the inhibitor being able to bind and inactivate the beta-lactamase molecules. Clavulanate, sulbactam and tazobactam are irreversible inactivators of many beta-lactamases, forming covalent complexes which resist hydrolysis. 'Suicide' kinetics are seen with some, but not all, enzymes. All three compounds inactivate staphylococcal penicillinase, the chromosomal beta-lactamases of Proteus vulgaris and Bacteroides spp., and the Class IV beta-lactamases present in some klebsiellae. Tazobactam, but not the other compounds, has moderate activity against some Class I (AmpC) chromosomal beta-lactamases, notably that of Morganella morganii, but not that of Enterobacter cloacae. Both clavulanate and tazobactam are strong inhibitors of the widely distributed TEM and SHV plasmid-mediated beta-lactamases; sulbactam is a weaker inhibitor. Other factors, aside from the affinity of the inhibitor for the enzyme, co-determine the success or failure of inhibition. Potentiation is most readily achieved if little enzyme is produced, and if the organism is very permeable to the inhibitor. Thus, resistance to inhibitor combinations is rare in strains of Haemophilus influenzae and Neisseria gonorrhoeae that produce TEM-beta-lactamase, but is commoner in enterobacteria that produce this enzyme, since these are less permeable and sometimes manufacture very large amounts of enzyme. The partner beta-lactam agent is also important. Irrespective of the inhibitor used, piperacillin is easier to protect against TEM beta-lactamases and the M. morganii Class I enzyme than are ampicillin, amoxycillin or ticarcillin. This may relate to the lower affinity of piperacillin for these enzymes, or to its greater affinity for the bacterial penicillin-binding proteins. Finally, pH can affect the degree of inhibition achieved with sulphones for some beta-lactamases, notably TEM-1.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8449836     DOI: 10.1093/jac/31.suppl_a.9

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  17 in total

1.  Variability of chromosomally encoded beta-lactamases from Klebsiella oxytoca.

Authors:  B Fournier; P H Roy
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

2.  Sulbactam Plays Neuronal Protective Effect Against Brain Ischemia via Upregulating GLT1 in Rats.

Authors:  Xin Cui; Li Li; Yu-Yan Hu; Shuang Ren; Min Zhang; Wen-Bin Li
Journal:  Mol Neurobiol       Date:  2014-07-27       Impact factor: 5.590

3.  Molecular characterization of TEM-59 (IRT-17), a novel inhibitor-resistant TEM-derived beta-lactamase in a clinical isolate of Klebsiella oxytoca.

Authors:  H Bermudes; F Jude; E B Chaibi; C Arpin; C Bebear; R Labia; C Quentin
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

4.  Pharmacodynamics of piperacillin alone and in combination with tazobactam against piperacillin-resistant and -susceptible organisms in an in vitro model of infection.

Authors:  A H Strayer; D H Gilbert; P Pivarnik; A A Medeiros; S H Zinner; M N Dudley
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

5.  Combinatorial Pharmacodynamics of Ceftolozane-Tazobactam against Genotypically Defined β-Lactamase-Producing Escherichia coli: Insights into the Pharmacokinetics/Pharmacodynamics of β-Lactam-β-Lactamase Inhibitor Combinations.

Authors:  Rachel L Soon; Justin R Lenhard; Zackery P Bulman; Patricia N Holden; Pamela Kelchlin; Judith N Steenbergen; Lawrence V Friedrich; Alan Forrest; Brian T Tsuji
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

Review 6.  Evolution of beta-lactamase inhibitors.

Authors:  D M Livermore
Journal:  Intensive Care Med       Date:  1994-07       Impact factor: 17.440

Review 7.  Three decades of beta-lactamase inhibitors.

Authors:  Sarah M Drawz; Robert A Bonomo
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

8.  In Vitro Activity of β-Lactams in Combination with β-Lactamase Inhibitors against Multidrug-Resistant Mycobacterium tuberculosis Isolates.

Authors:  Dan Zhang; Yufeng Wang; Jie Lu; Yu Pang
Journal:  Antimicrob Agents Chemother       Date:  2015-11-02       Impact factor: 5.191

Review 9.  Piperacillin/tazobactam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.

Authors:  H M Bryson; R N Brogden
Journal:  Drugs       Date:  1994-03       Impact factor: 9.546

10.  Inhibitor-sensitive AmpC beta-lactamase variant produced by an Escherichia coli clinical isolate resistant to oxyiminocephalosporins and cephamycins.

Authors:  Yohei Doi; Jun-ichi Wachino; Masaji Ishiguro; Hiroshi Kurokawa; Kunikazu Yamane; Naohiro Shibata; Keigo Shibayama; Keiko Yokoyama; Haru Kato; Tetsuya Yagi; Yoshichika Arakawa
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.